GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) to Present ProTEct-MS Study of Temelimab at MSVirtual2020
Geneva, Switzerland, September 8, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the company and the Karolinska Institutet’s Academic Specialist Center (ASC) will present the rationale of its new Phase 2 study at MSVirtual2020 (8th […]